Trials / Completed
CompletedNCT00310453
Tolerability of ALK Grass Tablet in Children
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of ALK Grass Tablet in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 5 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALK Grass tablet |
Timeline
- Start date
- 2006-03-01
- Completion
- 2006-05-01
- First posted
- 2006-04-04
- Last updated
- 2006-05-04
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00310453. Inclusion in this directory is not an endorsement.